德展健康(000813.SZ)擬向北京東方略增資 進一步加快在大健康領域技術研發和應用
格隆匯12月16日丨德展健康(000813.SZ)公佈，公司為進一步加快在大健康領域的技術研發和應用，通過投資驅動加速大健康產業鏈的佈局，公司與北京東方略生物醫藥科技股份有限公司(“北京東方略”、“標的公司”)及其原股東(上海仟德股權投資合夥企業(有限合夥)、仇思念、世耀生物醫藥技術(上海)有限公司、嘉興星空倍益投資合夥企業(有限合夥)、陳明鍵、深圳市熔巖奕新投資合夥企業(有限合夥)、楊維平、達孜東方高聖夏雨資本管理有限公司、上海展高股權投資合夥企業(有限合夥)、張馳、融智開普創業投資(北京)有限公司)經友好協商於2019年12月16日在北京市朝陽區共同簽署了《北京東方略生物醫藥科技股份有限公司增資協議》(“增資協議”)，公司擬對北京東方略進行增資，公司根據增資協議的條款和條件以其合法擁有的現金出資3億元認購標的公司此次新增3615萬股股份，超出新增註冊資本的金額2.6385億元計入標的公司的資本公積。北京東方略原股東一致同意將北京東方略的註冊資本由1.1953億元增加到1.5568億元。
北京東方略生物醫藥科技股份有限公司經營範圍：銷售醫療器械Ⅲ類；零售藥品；醫學研究與試驗發展；自然科學研究與試驗發展:技術開發、技術轉讓、技術諮詢、技術服務；技術進出口，貨物進出口、代理進出口；銷售醫療器械Ⅰ類、Ⅱ類。(企業依法自主選擇經營項目，開展經營活動:依法須經批准的項目，經相關部門批准後依批准的內容開展經營活動;不得從事本市產業政策禁止和限制類項目的經營活動。)
東方略是一家專注於腫瘤創新藥的臨牀開發和商業化的生物製藥企業，其重要品種為針對HPV宮頸癌癌前病變的DNA治療性疫苗VGX-3100在大中華區(中國內地、台灣、香港及澳門)專利及專有技術的獨家授權。此外，東方略還儲備有多款處於臨牀前/臨牀各階段產品。VGX-3100主要在研適應症為用於HPV16、HPV18型病毒感染導致的宮頸癌癌前病變的治療，改變宮頸癌癌前病變主要依靠宮頸錐切、切除子宮等創傷性手術治療手段的現狀，降低愈後復發的風險。同時，通過HPV病毒的清除，預防宮頸癌的形成，可進一步減少宮頸癌發病率。該產品在中國存在巨大的潛在市場空間。此次交易可幫助德展健康豐富自有產品線和拓展市場。為公司在腫瘤領域進行持續佈局，提高公司的行業影響力和綜合競爭力，符合公司中長期發展戰略。
此次交易定價參考評估值協商確定，交易價格公允，不存在損害公司及股東利益的情形。此次對外投資的項目預計短期對德展健康業績無實質影響，未來可成為新的利潤增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
